Merck KGaA Is Latest Partner For C4 Therapeutics’ Protein Degradation
New deal shows growing big pharma interest in protein degradation, with C4 expecting multiple in-house updates this year.
New deal shows growing big pharma interest in protein degradation, with C4 expecting multiple in-house updates this year.